Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the biotech’s share price up 30% and teeing up talks about filing for approval.
- Home |
- Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push
Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push
- February 17, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
